GZMK and renal cell carcinoma: GZMK was shown to be abundant in nivolumab-bound expanded CD8+ T cells in responding patients with renal cell carcinoma,9 and CD8+ GZMK+ cells were found to be significantly more abundant in patients with acute myeloid leukemia responding to ICI-based therapy compared to non-responders.28